Context Therapeutics Inc (CNTX) FinancialsCNTXContext Therapeutics Inc

Evaluating the bottom line, Context Therapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -76.14%, provide a clear picture of how effectively CNTX converts its operational activities into shareholder value.

In the context of the broader market, CNTX competes directly with industry leaders such as NEUP and KYNB. With a market capitalization of $17.85M, it holds a leading position in the sector. When comparing efficiency, CNTX's gross margin of N/A stands against NEUP's 100.00% and KYNB's -81.45%. Such benchmarking helps identify whether Context Therapeutics Inc is trading at a premium or discount relative to its financial performance.

The company has reported consistent financial losses, with a net income loss of $14.56 million in Q2 2026 and a negative EPS of -0.15. The gross profit has also been negative, indicating ongoing financial struggles.